ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

This study is testing a new drug called ELVN-001 for people with a type of blood cancer called chronic myeloid leukemia (CML) — a cancer where the bone marrow makes too many abnormal white blood cells. The study is specifically for Japanese patients whose CML has stopped responding to earlier treatments. **You may be eligible if...** - You have been diagnosed with a specific form of CML (BCR::ABL1-positive, chronic phase) - At least 2 prior CML medications (called TKIs or tyrosine kinase inhibitors) have not worked for you, you could not tolerate them, or you are not a candidate for them - You were born in Japan and all four of your grandparents are Japanese - You are reasonably fit and able to carry out daily activities (ECOG 0-2) - Your blood, liver, and kidney function are adequate - If you had a bone marrow transplant, it was at least 6 months ago **You may NOT be eligible if...** - You received cancer treatment within the past 7 days (or within 5 half-lives of the drug) - You have a history of severe pancreatitis (pancreas inflammation) caused by a TKI drug in the last 6 months, or you have active chronic pancreatitis - Your heart has an abnormal electrical pattern (prolonged QTc interval over 470 ms on an ECG) Talk to your doctor to see if this trial is right for you.